S&P 500   3,940.40 (+0.61%)
DOW   32,134.98 (+0.86%)
QQQ   305.41 (+0.02%)
AAPL   157.62 (+1.69%)
MSFT   271.27 (-2.92%)
META   197.41 (+0.92%)
GOOGL   101.19 (-0.42%)
AMZN   97.12 (-1.85%)
TSLA   183.41 (+1.82%)
NVDA   259.49 (+0.87%)
NIO   8.69 (+5.21%)
BABA   80.79 (-1.08%)
AMD   95.72 (-2.17%)
T   18.47 (+1.88%)
F   11.24 (-0.53%)
MU   57.21 (+0.97%)
CGC   1.88 (-6.00%)
GE   90.27 (-0.02%)
DIS   93.93 (+0.78%)
AMC   4.29 (+2.63%)
PFE   40.63 (+1.32%)
PYPL   72.58 (-0.56%)
NFLX   304.00 (+0.16%)
S&P 500   3,940.40 (+0.61%)
DOW   32,134.98 (+0.86%)
QQQ   305.41 (+0.02%)
AAPL   157.62 (+1.69%)
MSFT   271.27 (-2.92%)
META   197.41 (+0.92%)
GOOGL   101.19 (-0.42%)
AMZN   97.12 (-1.85%)
TSLA   183.41 (+1.82%)
NVDA   259.49 (+0.87%)
NIO   8.69 (+5.21%)
BABA   80.79 (-1.08%)
AMD   95.72 (-2.17%)
T   18.47 (+1.88%)
F   11.24 (-0.53%)
MU   57.21 (+0.97%)
CGC   1.88 (-6.00%)
GE   90.27 (-0.02%)
DIS   93.93 (+0.78%)
AMC   4.29 (+2.63%)
PFE   40.63 (+1.32%)
PYPL   72.58 (-0.56%)
NFLX   304.00 (+0.16%)
S&P 500   3,940.40 (+0.61%)
DOW   32,134.98 (+0.86%)
QQQ   305.41 (+0.02%)
AAPL   157.62 (+1.69%)
MSFT   271.27 (-2.92%)
META   197.41 (+0.92%)
GOOGL   101.19 (-0.42%)
AMZN   97.12 (-1.85%)
TSLA   183.41 (+1.82%)
NVDA   259.49 (+0.87%)
NIO   8.69 (+5.21%)
BABA   80.79 (-1.08%)
AMD   95.72 (-2.17%)
T   18.47 (+1.88%)
F   11.24 (-0.53%)
MU   57.21 (+0.97%)
CGC   1.88 (-6.00%)
GE   90.27 (-0.02%)
DIS   93.93 (+0.78%)
AMC   4.29 (+2.63%)
PFE   40.63 (+1.32%)
PYPL   72.58 (-0.56%)
NFLX   304.00 (+0.16%)
S&P 500   3,940.40 (+0.61%)
DOW   32,134.98 (+0.86%)
QQQ   305.41 (+0.02%)
AAPL   157.62 (+1.69%)
MSFT   271.27 (-2.92%)
META   197.41 (+0.92%)
GOOGL   101.19 (-0.42%)
AMZN   97.12 (-1.85%)
TSLA   183.41 (+1.82%)
NVDA   259.49 (+0.87%)
NIO   8.69 (+5.21%)
BABA   80.79 (-1.08%)
AMD   95.72 (-2.17%)
T   18.47 (+1.88%)
F   11.24 (-0.53%)
MU   57.21 (+0.97%)
CGC   1.88 (-6.00%)
GE   90.27 (-0.02%)
DIS   93.93 (+0.78%)
AMC   4.29 (+2.63%)
PFE   40.63 (+1.32%)
PYPL   72.58 (-0.56%)
NFLX   304.00 (+0.16%)
NASDAQ:ALVR

AlloVir - ALVR Stock Forecast, Price & News

$4.43
-0.12 (-2.64%)
(As of 03/20/2023 02:24 PM ET)
Add
Compare
Today's Range
$3.93
$4.44
50-Day Range
$4.55
$7.05
52-Week Range
$3.17
$10.29
Volume
408,296 shs
Average Volume
275,801 shs
Market Capitalization
$414.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.33

AlloVir MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
449.3% Upside
$24.33 Price Target
Short Interest
Bearish
5.80% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$219,126 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.89) to ($1.98) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.69 out of 5 stars

Medical Sector

818th out of 983 stocks

Biological Products, Except Diagnostic Industry

141st out of 161 stocks


ALVR stock logo

About AlloVir (NASDAQ:ALVR) Stock

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

Receive ALVR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AlloVir and its competitors with MarketBeat's FREE daily newsletter.

ALVR Stock News Headlines

AlloVir Appoints Derek Adams, Ph.D., to Board of Directors
SVB Securities Reaffirms Their Buy Rating on AlloVir (ALVR)
Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
AlloVir Reports Third Quarter 2022 Financial Results
The 'Big Picture' Isn't Pretty - RealMoney - RealMoney
ALVR Crosses Above Key Moving Average Level
Analysts See 25% Gains Ahead For IWN - Nasdaq
See More Headlines
Receive ALVR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AlloVir and its competitors with MarketBeat's FREE daily newsletter.

ALVR Company Calendar

Last Earnings
8/05/2021
Today
3/20/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALVR
Fax
N/A
Employees
107
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$24.33
High Stock Price Forecast
$34.00
Low Stock Price Forecast
$19.00
Forecasted Upside/Downside
+499.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-168,710,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.41 per share

Miscellaneous

Free Float
42,787,000
Market Cap
$379.45 million
Optionable
Not Optionable
Beta
0.85

Key Executives

  • Mr. David L. HallalMr. David L. Hallal (Age 57)
    Exec. Chairman
    Comp: $395.6k
  • Dr. Diana M. Brainard M.D. (Age 52)
    CEO & Director
    Comp: $1.52M
  • Mr. Vikas Sinha C.A. (Age 60)
    CPA, M.B.A., Pres, CFO & Director
    Comp: $622.25k
  • Dr. Jeroen van Beek Ph.D. (Age 59)
    Consultant
    Comp: $601k
  • Mr. Agustin Melian M.D.Mr. Agustin Melian M.D. (Age 59)
    Advisor
    Comp: $1.37M
  • Mr. Brett R. HagenMr. Brett R. Hagen (Age 50)
    Chief Accounting Officer
  • Mr. Dana M. Alexander M.B.A. (Age 47)
    Sr. VP of Technical Operations
  • Dr. Ann M. Leen Ph.D. (Age 46)
    Chief Scientific Officer
  • Ms. Sonia Choi
    Sr. VP of Corp. Affairs & Investor Relations
  • Mr. Edward Miller J.D. (Age 58)
    Gen. Counsel & Sec.













ALVR Stock - Frequently Asked Questions

Should I buy or sell AlloVir stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AlloVir in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ALVR shares.
View ALVR analyst ratings
or view top-rated stocks.

What is AlloVir's stock price forecast for 2023?

3 equities research analysts have issued twelve-month price targets for AlloVir's shares. Their ALVR share price forecasts range from $19.00 to $34.00. On average, they expect the company's stock price to reach $24.33 in the next year. This suggests a possible upside of 499.3% from the stock's current price.
View analysts price targets for ALVR
or view top-rated stocks among Wall Street analysts.

How have ALVR shares performed in 2023?

AlloVir's stock was trading at $5.13 at the beginning of the year. Since then, ALVR shares have decreased by 20.9% and is now trading at $4.06.
View the best growth stocks for 2023 here
.

Are investors shorting AlloVir?

AlloVir saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 5,420,000 shares, an increase of 20.4% from the February 13th total of 4,500,000 shares. Based on an average daily volume of 257,100 shares, the days-to-cover ratio is currently 21.1 days.
View AlloVir's Short Interest
.

When is AlloVir's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our ALVR earnings forecast
.

How were AlloVir's earnings last quarter?

AlloVir, Inc. (NASDAQ:ALVR) posted its earnings results on Thursday, August, 5th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.46) by $0.14.

What other stocks do shareholders of AlloVir own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AlloVir investors own include Advanced Micro Devices (AMD), Cloudera (CLDR), Infinera (INFN), Sonos (SONO), Trevena (TRVN), Abbott Laboratories (ABT), Boeing (BA), Delta Air Lines (DAL), Datadog (DDOG) and FuelCell Energy (FCEL).

When did AlloVir IPO?

(ALVR) raised $252 million in an IPO on Thursday, July 30th 2020. The company issued 14,800,000 shares at $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

What is AlloVir's stock symbol?

AlloVir trades on the NASDAQ under the ticker symbol "ALVR."

Who are AlloVir's major shareholders?

AlloVir's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Alkeon Capital Management LLC (4.94%), JPMorgan Chase & Co. (1.03%), Geode Capital Management LLC (0.82%), Renaissance Technologies LLC (0.44%), Charles Schwab Investment Management Inc. (0.33%) and Morgan Stanley (0.24%). Insiders that own company stock include Agustin Melian, Ann M Leen, Beek Jeroen B Van, Beek Jeroen B Van, Brett R Hagen, David Hallal, Diana Brainard, Edward Miller, Ercem Atillasoy, Jeffrey S Bornstein, John Robert Wilson, Juan Vera, Morana Jovan-Embiricos and Vikas Sinha.
View institutional ownership trends
.

How do I buy shares of AlloVir?

Shares of ALVR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AlloVir's stock price today?

One share of ALVR stock can currently be purchased for approximately $4.06.

How much money does AlloVir make?

AlloVir (NASDAQ:ALVR) has a market capitalization of $379.45 million. The company earns $-168,710,000.00 in net income (profit) each year or ($2.25) on an earnings per share basis.

How many employees does AlloVir have?

The company employs 107 workers across the globe.

How can I contact AlloVir?

AlloVir's mailing address is 139 MAIN STREET SUITE 500, CAMBRIDGE MA, 02142. The official website for the company is www.allovir.com. The company can be reached via phone at 617-433-2605 or via email at ir@allovir.com.

This page (NASDAQ:ALVR) was last updated on 3/20/2023 by MarketBeat.com Staff